Serge V Muyldermans

List of Publications by Year
in descending order

279	26,829	6613	7348
papers	citations	79 h-index	152 g-index

291	291	291	16152
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Naturally occurring antibodies devoid of light chains. Nature, 1993, 363, 446-448.	27.8	2,600
2	Nanobodies: Natural Single-Domain Antibodies. Annual Review of Biochemistry, 2013, 82, 775-797.	11.1	1,602
3	Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Letters, 1997, 414, 521-526.	2.8	646
4	A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins. Molecular and Cellular Proteomics, 2008, 7, 282-289.	3.8	616
5	Targeting and tracing antigens in live cells with fluorescent nanobodies. Nature Methods, 2006, 3, 887-889.	19.0	613
6	A general protocol for the generation of Nanobodies for structural biology. Nature Protocols, 2014, 9, 674-693.	12.0	571
7	Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4586-4591.	7.1	541
8	Single-domain antibody fragments with high conformational stability. Protein Science, 2009, 11, 500-515.	7.6	501
9	Modulation of protein properties in living cells using nanobodies. Nature Structural and Molecular Biology, 2010, 17, 133-138.	8.2	494
10	Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nature Structural and Molecular Biology, 1996, 3, 803-811.	8.2	448
11	General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold. Journal of Biological Chemistry, 2009, 284, 3273-3284.	3.4	441
12	The Therapeutic Potential of Nanobodies. BioDrugs, 2020, 34, 11-26.	4.6	435
13	Camelid immunoglobulins and nanobody technology. Veterinary Immunology and Immunopathology, 2009, 128, 178-183.	1.2	424
14	Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO Journal, 1998, 17, 3512-3520.	7.8	421
15	Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Engineering, Design and Selection, 1994, 7, 1129-1135.	2.1	407
16	Nanobody-based products as research and diagnostic tools. Trends in Biotechnology, 2014, 32, 263-270.	9.3	341
17	Specific Cell Targeting with Nanobody Conjugated Branched Gold Nanoparticles for Photothermal Therapy. ACS Nano, 2011, 5, 4319-4328.	14.6	338
18	Efficient Cancer Therapy with a Nanobody-Based Conjugate. Cancer Research, 2004, 64, 2853-2857.	0.9	318

#	Article	IF	Citations
19	Î²-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae. Antimicrobial Agents and Chemotherapy, 2001, 45, 2807-2812.	3.2	301
20	Single domain camel antibodies: current status. Reviews in Molecular Biotechnology, 2001, 74, 277-302.	2.8	291
21	Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends in Biochemical Sciences, 2001, 26, 230-235.	7.5	283
22	Comparison of llama VH sequences from conventional and heavy chain antibodies. Molecular Immunology, 1997, 34, 1121-1131.	2.2	271
23	Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs. Journal of Biological Chemistry, 2001, 276, 7346-7350.	3.4	268
24	Nanobodies and their potential applications. Nanomedicine, 2013, 8, 1013-1026.	3.3	252
25	Preclinical screening of antiâ€HER2 nanobodies for molecular imaging of breast cancer. FASEB Journal, 2011, 25, 2433-2446.	0.5	246
26	Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire. EMBO Journal, 2000, 19, 921-930.	7.8	243
27	Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies. Journal of Biological Chemistry, 2004, 279, 1256-1261.	3.4	238
28	ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nature Methods, 2007, 4, 13-17.	19.0	231
29	Efficient tumor targeting by single-domain antibody fragments of camels. International Journal of Cancer, 2002, 98, 456-462.	5.1	228
30	A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature, 2003, 424, 783-788.	27.8	227
31	Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. Biosensors and Bioelectronics, 2005, 21, 483-490.	10.1	209
32	Position and orientation of the globular domain of linker histone H5 on the nucleosome. Nature, 1998, 395, 402-405.	27.8	205
33	Nanobodies as novel agents for cancer therapy. Expert Opinion on Biological Therapy, 2005, 5, 111-124.	3.1	196
34	Nanobodies and recombinant binders in cell biology. Journal of Cell Biology, 2015, 209, 633-644.	5.2	195
35	Identification of a Universal VHH Framework to Graft Non-canonical Antigen-binding Loops of Camel Single-domain Antibodies. Journal of Molecular Biology, 2005, 352, 597-607.	4.2	194
36	Single-domain antibodies as building blocks for novel therapeutics. Current Opinion in Pharmacology, 2008, 8, 600-608.	3.5	173

#	Article	IF	Citations
37	Synthesis, Preclinical Validation, Dosimetry, and Toxicity of ⁶⁸Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer. Journal of Nuclear Medicine, 2013, 54, 776-784.	5.0	173
38	Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions. Circulation Research, 2012, 110, 927-937.	4.5	167
39	Targeted Radionuclide Therapy with A ¹⁷⁷Lu-labeled Anti-HER2 Nanobody. Theranostics, 2014, 4, 708-720.	10.0	165
40	Antibody repertoire development in camelids. Developmental and Comparative Immunology, 2006, 30, 187-198.	2.3	164
41	A Case Of Convergence: Why Did a Simple Alternative to Canonical Antibodies Arise in Sharks and Camels?. PLoS Biology, 2011, 9, e1001120.	5.6	159
42	A guide to: generation and design of nanobodies. FEBS Journal, 2021, 288, 2084-2102.	4.7	153
43	A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure, 1999, 7, 361-370.	3.3	150
44	Three Camelid VHH Domains in Complex with Porcine Pancreatic Î±-Amylase. Journal of Biological Chemistry, 2002, 277, 23645-23650.	3.4	145
45	Applications of Nanobodies. Annual Review of Animal Biosciences, 2021, 9, 401-421.	7.4	144
46	Emergence and evolution of functional heavy-chain antibodies in Camelidae. Developmental and Comparative Immunology, 2003, 27, 87-103.	2.3	143
47	Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody. Journal of Biological Chemistry, 2001, 276, 26285-26290.	3.4	141
48	Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nature Medicine, 2006, 12, 580-584.	30.7	140
49	Disulfide Bond Introduction for General Stabilization of Immunoglobulin Heavy-Chain Variable Domains. Journal of Molecular Biology, 2008, 377, 478-488.	4.2	140
50	Site-Specific Labeling of Cysteine-Tagged Camelid Single-Domain Antibody-Fragments for Use in Molecular Imaging. Bioconjugate Chemistry, 2014, 25, 979-988.	3.6	135
51	Antibody Fragments as Probe in Biosensor Development. Sensors, 2008, 8, 4669-4686.	3.8	134
52	Functional heavy-chain antibodies in camelidae. Advances in Immunology, 2001, 79, 261-296.	2.2	131
53	Single domain antibodies: comparison of camel VH and camelised human VH domains. Journal of Immunological Methods, 1999, 231, 25-38.	1.4	127
54	A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB Journal, 2010, 24, 3479-3489.	0.5	126

#	Article	IF	Citations
55	Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy. Frontiers in Immunology, 2017, 8, 1442.	4.8	126
56	Generation of Single Domain Antibody Fragments Derived from Camelids and Generation of Manifold Constructs. Methods in Molecular Biology, 2012, 907, 145-176.	0.9	124
57	VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin Aahlâ€². Molecular Immunology, 2008, 45, 3847-3856.	2.2	123
58	Single Domain Antibodies Derived from Dromedary Lymph Node and Peripheral Blood Lymphocytes Sensing Conformational Variants of Prostate-specific Antigen. Journal of Biological Chemistry, 2004, 279, 51965-51972.	3.4	120
59	Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. Journal of Molecular Recognition, 1999, 12, 131-140.	2.1	119
60	Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opinion on Biological Therapy, 2016, 16, 1035-1047.	3.1	119
61	Dual Beneficial Effect of Interloop Disulfide Bond for Single Domain Antibody Fragments. Journal of Biological Chemistry, 2012, 287, 1970-1979.	3.4	113
62	Crystal Structure of the Intrinsically Flexible Addiction Antidote MazE. Journal of Biological Chemistry, 2003, 278, 28252-28257.	3.4	109
63	Localization, mechanism and reduction of renal retention of technetiumâ€99m labeled epidermal growth factor receptorâ€specific nanobody in mice. Contrast Media and Molecular Imaging, 2011, 6, 85-92.	0.8	108
64	Engineering Camel Single-Domain Antibodies and Immobilization Chemistry for Human Prostate-Specific Antigen Sensing. Analytical Chemistry, 2005, 77, 7547-7555.	6.5	106
65	In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT. Journal of Nuclear Medicine, 2010, 51, 1099-1106.	5.0	106
66	The structural basis of nanobody unfolding reversibility and thermoresistance. Scientific Reports, 2018, 8, 7934.	3.3	106
67	Camelid single-domain antibody-fragment engineering for (pre)clinicalin vivomolecular imaging applications: adjusting the bullet to its target. Expert Opinion on Biological Therapy, 2013, 13, 1149-1160.	3.1	105
68	Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types. Journal of Nuclear Medicine, 2010, 51, 782-789.	5.0	102
69	Loss of splice consensus signal is responsible for the removal of the entire CH1 domain of the functional camel IGG2A heavy-chain antibodies11This work was supported by the VLIR, VIB and FGWO.. Molecular Immunology, 1999, 36, 515-524.	2.2	100
70	Reduced Global Cooperativity is a Common Feature Underlying the Amyloidogenicity of Pathogenic Lysozyme Mutations. Journal of Molecular Biology, 2005, 346, 773-788.	4.2	100
71	Sortase Aâ€mediated siteâ€specific labeling of camelid singleâ€domain antibodyâ€fragments: a versatile strategy for multiple molecular imaging modalities. Contrast Media and Molecular Imaging, 2016, 11, 328-339.	0.8	100
72	Homo- and Heteronuclear Two-Dimensional NMR Studies of the Globular Domain of Histone H1: Full Assignment, Tertiary Structure, and Comparison with the Globular Domain of Histone H5. Biochemistry, 1994, 33, 11079-11086.	2.5	98

#	Article	IF	Citations
73	Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Molecular Immunology, 2012, 50, 35-41.	2.2	97
74	Immunogenicity Risk Profile of Nanobodies. Frontiers in Immunology, 2021, 12, 632687.	4.8	97
75	Canonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes?. Journal of Molecular Biology, 2000, 300, 83-91.	4.2	93
76	Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. , 1998, 32, 515-522.		92
77	An S-Layer Heavy Chain Camel Antibody Fusion Protein for Generation of a Nanopatterned Sensing Layer To Detect the Prostate-Specific Antigen by Surface Plasmon Resonance Technology. Bioconjugate Chemistry, 2004, 15, 664-671.	3.6	92
78	Antigen Binding and Solubility Effects upon the Veneering of a Camel VHH in Framework-2 to Mimic a VH. Journal of Molecular Biology, 2005, 350, 112-125.	4.2	90
79	Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opinion on Drug Delivery, 2014, 11, 1939-1954.	5.0	88
80	Structural Insights into Polymorphic ABO Glycan Binding by Helicobacter pylori. Cell Host and Microbe, 2016, 19, 55-66.	11.0	88
81	Nanobodies as Probes for Protein Dynamics in Vitro and in Cells. Journal of Biological Chemistry, 2016, 291, 3767-3775.	3.4	84
82	The specific variable domain of camel heavy-chain antibodies is encoded in the germline. Journal of Molecular Biology, 1998, 275, 413-418.	4.2	83
83	Nanobody-coupled microbubbles as novel molecular tracer. Journal of Controlled Release, 2012, 158, 346-353.	9.9	78
84	Nanobodies^{Â®}: proficient tools in diagnostics. Expert Review of Molecular Diagnostics, 2010, 10, 777-785.	3.1	75
85	Introduction to Heavy Chain Antibodies and Derived Nanobodies. , 2012, 911, 15-26.		75
86	Animal Immunization, in Vitro Display Technologies, and Machine Learning for Antibody Discovery. Trends in Biotechnology, 2021, 39, 1263-1273.	9.3	74
87	Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. International Journal for Parasitology, 2009, 39, 625-633.	3.1	72
88	Ultrasensitive Measurement of Ca²⁺ Influx into Lipid Vesicles Induced by Protein Aggregates. Angewandte Chemie - International Edition, 2017, 56, 7750-7754.	13.8	72
89	Development of ¹⁷⁷Luâ€nanobodies for radioimmunotherapy of HER2â€positive breast cancer: evaluation of different bifunctional chelators. Contrast Media and Molecular Imaging, 2012, 7, 254-264.	0.8	70
90	A Novel Promiscuous Class of Camelid Single-Domain Antibody Contributes to the Antigen-Binding Repertoire. Journal of Immunology, 2010, 184, 5696-5704.	0.8	68

#	Article	IF	Citations
91	Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. New Biotechnology, 2013, 30, 205-209.	4.4	68
92	Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Leukemia, 2014, 28, 444-447.	7.2	68
93	Chemical Basis for the Affinity Maturation of a Camel Single Domain Antibody. Journal of Biological Chemistry, 2004, 279, 53593-53601.	3.4	66
94	Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains. BMC Biotechnology, 2007, 7, 7.	3.3	66
95	Engineering a Camelid Antibody Fragment That Binds to the Active Site of Human Lysozyme and Inhibits Its Conversion into Amyloid Fibrils. Biochemistry, 2008, 47, 11041-11054.	2.5	66
96	Nanoimmunoassay onto a screen printed electrode for HER2 breast cancer biomarker determination. Talanta, 2014, 130, 164-170.	5.5	66
97	A nanobody-based electrochemiluminescent immunosensor for sensitive detection of human procalcitonin. Analyst, The, 2014, 139, 3718.	3.5	66
98	Heavy-chain antibodies in Camelidae ; a case of evolutionary innovation. Immunogenetics, 2002, 54, 39-47.	2.4	64
99	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimerâ€™s disease progression. Acta Neuropathologica Communications, 2019, 7, 120.	5.2	64
100	Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens. Journal of Immunological Methods, 2008, 329, 138-150.	1.4	61
101	Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition. Frontiers in Immunology, 2018, 9, 2278.	4.8	60
102	Homo- and heteronuclear two-dimensional NMR studies of the globular domain of histone H1: Sequential assignment and secondary structure. Biochemistry, 1993, 32, 11345-11351.	2.5	58
103	High Affinity Nanobodies against the Trypanosome brucei VSG Are Potent Trypanolytic Agents that Block Endocytosis. PLoS Pathogens, 2011, 7, e1002072.	4.7	58
104	Generation of a Functional Monomolecular Protein Lattice Consisting of an S-Layer Fusion Protein Comprising the Variable Domain of a Camel Heavy Chain Antibody. Bioconjugate Chemistry, 2003, 14, 440-448.	3.6	57
105	Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. Contrast Media and Molecular Imaging, 2014, 9, 211-220.	0.8	57
106	Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics, 2017, 16, 2828-2839.	4.1	57
107	Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. Biochemical Journal, 2009, 424, 263-272.	3.7	56
108	Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies. Biochemical Journal, 2014, 459, 59-69.	3.7	56

#	Article	IF	Citations
109	Single-Domain Antibodies Targeting Neuraminidase Protect against an H5N1 Influenza Virus Challenge. Journal of Virology, 2014, 88, 8278-8296.	3.4	56
110	Nanobodyâ€mediated resistance to Grapevine fanleaf virus in plants. Plant Biotechnology Journal, 2018, 16, 660-671.	8.3	55
111	DNA Sequence Organization in Chromatosomes. Journal of Molecular Biology, 1994, 235, 855-870.	4.2	54
112	Surface display of a single-domain antibody library on Gram-positive bacteria. Cellular and Molecular Life Sciences, 2013, 70, 1081-1093.	5.4	53
113	Strong in Vivo Maturation Compensates for Structurally Restricted H3 Loops in Antibody Repertoires. Journal of Biological Chemistry, 2005, 280, 14114-14121.	3.4	52
114	Correlation Between Epidermal Growth Factor Receptor-Specific Nanobody Uptake and Tumor Burden: A Tool for Noninvasive Monitoring of Tumor Response to Therapy. Molecular Imaging and Biology, 2011, 13, 940-948.	2.6	51
115	Minimum information about a protein affinity reagent (MIAPAR). Nature Biotechnology, 2010, 28, 650-653.	17.5	50
116	Development of a Nanobody-based lateral flow assay to detect active Trypanosoma congolense infections. Scientific Reports, 2018, 8, 9019.	3.3	49
117	Degenerate interfaces in antigen-antibody complexes. Journal of Molecular Biology, 2001, 313, 473-478.	4.2	48
118	Direct Injection of Functional Single-Domain Antibodies from E. coli into Human Cells. PLoS ONE, 2010, 5, e15227.	2.5	48
119	A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines. Cellular and Molecular Life Sciences, 2010, 67, 3371-3387.	5.4	47
120	Molecular Imaging with Macrophage CRIg-Targeting Nanobodies for Early and Preclinical Diagnosis in a Mouse Model of Rheumatoid Arthritis. Journal of Nuclear Medicine, 2014, 55, 824-829.	5.0	47
121	Distinct antibody species: structural differences creating therapeutic opportunities. Current Opinion in Immunology, 2016, 40, 7-13.	5.5	47
122	Kinetic and Affinity Predictions of a Protein-Protein Interaction Using Multivariate Experimental Design. Journal of Biological Chemistry, 2002, 277, 29897-29907.	3.4	46
123	A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies. Archives of Biochemistry and Biophysics, 2012, 526, 114-123.	3.0	46
124	Formation, stability and core histone positioning of nucleosomes reassembled on bent and other nucleosome-derived DNA. Journal of Molecular Biology, 1989, 207, 183-192.	4.2	45
125	Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers. Frontiers in Immunology, 2017, 8, 1746.	4.8	45
126	Evaluation of a nanobody phage display library constructed from a Brucella-immunised camel. Veterinary Immunology and Immunopathology, 2011, 142, 49-56.	1.2	44

#	Article	IF	Citations
127	Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates. Oncotarget, 2017, 8, 44141-44158.	1.8	44
128	Using microdialysis to analyse the passage of monovalent nanobodies through the bloodâ€“brain barrier. British Journal of Pharmacology, 2012, 165, 2341-2353.	5.4	42
129	A Nanobody Binding to Non-Amyloidogenic Regions of the Protein Human Lysozyme Enhances Partial Unfolding but Inhibits Amyloid Fibril Formation. Journal of Physical Chemistry B, 2013, 117, 13245-13258.	2.6	42
130	Individual aggregates of amyloid beta induce temporary calcium influx through the cell membrane of neuronal cells. Scientific Reports, 2016, 6, 31910.	3.3	42
131	A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells. Scientific Reports, 2017, 7, 15130.	3.3	41
132	Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis, 2010, 8, 1302-1312.	3.8	40
133	Emerging site-specific bioconjugation strategies for radioimmunotracer development. Expert Opinion on Drug Delivery, 2016, 13, 1149-1163.	5.0	40
134	Upon the observation of superbeads in chromatin. Nucleic Acids Research, 1980, 8, 2165-2172.	14.5	39
135	In vitro antiviral activity of single domain antibody fragments against poliovirus. Antiviral Research, 2010, 87, 257-264.	4.1	38
136	Exploiting sequence and stability information for directing nanobody stability engineering. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2196-2205.	2.4	38
137	Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies. Current Pharmaceutical Design, 2017, 22, 6500-6518.	1.9	37
138	A DNA Sequence for Positioning Chromatosomes. Journal of Molecular Biology, 1996, 257, 486-491.	4.2	36
139	Limiting the protein corona: A successful strategy for inÂvivo active targeting of anti-HER2 nanobody-functionalized nanostars. Biomaterials, 2017, 123, 15-23.	11.4	36
140	Functionalization of gold nanoparticles with nanobodies through physical adsorption. Analytical Methods, 2017, 9, 3430-3440.	2.7	36
141	Selection of specific nanobodies to develop an immuno-assay detecting Staphylococcus aureus in milk. Food Chemistry, 2021, 353, 129481.	8.2	36
142	VHH (nanobody) directed against human glycophorin A: A tool for autologous red cell agglutination assays. Analytical Biochemistry, 2013, 438, 82-89.	2.4	35
143	Inactivation of Î³â€secretases leads to accumulation of substrates and nonâ€Alzheimer neurodegeneration. EMBO Molecular Medicine, 2017, 9, 1088-1099.	6.9	35
144	Differences in rearrangements of H1 and H5 in chicken erythrocyte chromatin. Biochemistry, 1981, 20, 1104-1110.	2.5	33

#	Article	IF	Citations
145	Interactions between Metal-binding Domains Modulate Intracellular Targeting of Cu(I)-ATPase ATP7B, as Revealed by Nanobody Binding. Journal of Biological Chemistry, 2014, 289, 32682-32693.	3.4	33
146	Camelid nanobodies with high affinity for broad bean mottle virus: a possible promising tool to immunomodulate plant resistance against viruses. Plant Molecular Biology, 2015, 87, 355-369.	3.9	33
147	An overview on display systems (phage, bacterial, and yeast display) for production of anticancer antibodies; advantages and disadvantages. International Journal of Biological Macromolecules, 2022, 208, 421-442.	7.5	33
148	A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior. Journal of Biological Chemistry, 2016, 291, 15156-15168.	3.4	32
149	Different residues in periplasmic domains of the CcmC inner membrane protein of Pseudomonas fluorescens ATCC 17400 are critical for cytochrome c biogenesis and pyoverdine-mediated iron uptake. Molecular Microbiology, 1998, 30, 547-555.	2.5	31
150	Development of Cys38 knock-out and humanized version of NbAahII10 nanobody with improved neutralization of AahII Scorpion toxin. Protein Engineering, Design and Selection, 2011, 24, 727-735.	2.1	30
151	An Anti-proteome Nanobody Library Approach Yields a Specific Immunoassay for Trypanosoma congolense Diagnosis Targeting Glycosomal Aldolase. PLoS Neglected Tropical Diseases, 2016, 10, e0004420.	3.0	30
152	Nanobodies as novel therapeutic agents in envenomation. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 2955-2965.	2.4	30
153	Chaperonin GroEL a Brucella immunodominant antigen identified using Nanobody and MALDI-TOF-MS technologies. Veterinary Immunology and Immunopathology, 2012, 146, 254-263.	1.2	29
154	Application of Single-Domain Antibodies (â€œNanobodiesâ€) to Laboratory Diagnosis. Annals of Laboratory Medicine, 2021, 41, 549-558.	2.5	29
155	Neutron scattering studies of chromatosomes. Biochemical and Biophysical Research Communications, 1991, 179, 810-816.	2.1	28
156	Camelid nanobodies raised against an integral membrane enzyme, nitric oxide reductase. Protein Science, 2009, 18, 619-628.	7.6	28
157	Development of Nanobodies Against Hemorrhagic and Myotoxic Components of Bothrops atrox Snake Venom. Frontiers in Immunology, 2020, 11, 655.	4.8	28
158	Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells. Immunology, 2003, 109, 93-101.	4.4	27
159	Expression of a Dromedary Heavy Chain-Only Antibody and B Cell Development in the Mouse. Journal of Immunology, 2005, 175, 3769-3779.	0.8	27
160	Pre-clinical studies of toxin-specific Nanobodies: Evidence of in vivo efficacy to prevent fatal disturbances provoked by scorpion envenoming. Toxicology and Applied Pharmacology, 2012, 264, 222-231.	2.8	27
161	Monitoring liver macrophages using nanobodies targeting Vsig4: Concanavalin A induced acute hepatitis as paradigm. Immunobiology, 2015, 220, 200-209.	1.9	27
162	Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator. Scientific Reports, 2017, 7, 3385.	3.3	27

#	Article	IF	Citations
163	Novel halfâ€life extended antiâ€MIF nanobodies protect against endotoxic shock. FASEB Journal, 2018, 32, 3411-3422.	0.5	27
164	Mechanisms Underlying Connexin Hemichannel Activation in Disease. International Journal of Molecular Sciences, 2021, 22, 3503.	4.1	27
165	Generation and characterization of non-competitive furin-inhibiting nanobodies. Biochemical Journal, 2012, 448, 73-82.	3.7	26
166	TRIM28 and Î²-Actin Identified via Nanobody-Based Reverse Proteomics Approach as Possible Human Glioblastoma Biomarkers. PLoS ONE, 2014, 9, e113688.	2.5	26
167	Generation of a Nanobody Targeting the Paraflagellar Rod Protein of Trypanosomes. PLoS ONE, 2014, 9, e115893.	2.5	26
168	Molecular analysis of heavy chain-only antibodies of Camelus bactrianus. Biochemistry (Moscow), 2014, 79, 1382-1390.	1.5	26
169	A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation. FASEB Journal, 2014, 28, 4004-4014.	0.5	26
170	Construction of High-Quality Camel Immune Antibody Libraries. Methods in Molecular Biology, 2018, 1701, 169-187.	0.9	26
171	The Development and Validation of a Novel Nanobody-Based Competitive ELISA for the Detection of Foot and Mouth Disease 3ABC Antibodies in Cattle. Frontiers in Veterinary Science, 2018, 5, 250.	2.2	26
172	The structural organization of dinudeosomes and oligonucleosomes. Electric dichroism and birefringence study. Nucleic Acids Research, 1981, 9, 5763-5784.	14.5	25
173	NanobodyÂ®-based chromatin immunoprecipitation/micro-array analysis for genome-wide identification of transcription factor DNA binding sites. Nucleic Acids Research, 2013, 41, e59-e59.	14.5	25
174	Specific Targeting of Atherosclerotic Plaques in ApoEâ^'/â^' Mice Using a New Camelid sdAb Binding the Vulnerable Plaque Marker LOX-1. Molecular Imaging and Biology, 2014, 16, 690-698.	2.6	25
175	Development of a monoâ€specific antiâ€VEGF bivalent nanobody with extended plasma halfâ€life for treatment of pathologic neovascularization. Drug Testing and Analysis, 2020, 12, 92-100.	2.6	25
176	99mTc-Labeled Nanobodies: A New Type of Targeted Probes for Imaging Antigen Expression. Current Radiopharmaceuticals, 2008, 1, 37-41.	0.8	24
177	Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis. Molecular Imaging and Biology, 2017, 19, 49-58.	2.6	24
178	DNA recombination associated with short direct repeats in Leishmania mexicana M379. Molecular and Biochemical Parasitology, 1992, 50, 351-353.	1.1	23
179	Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity. Immunobiology, 2017, 222, 807-813.	1.9	23
180	Epitope structure and binding affinity of single chain llama antiâ€Î²â€amyloid antibodies revealed by proteolytic excision affinityâ€mass spectrometry. Journal of Molecular Recognition, 2013, 26, 1-9.	2.1	22

#	Article	IF	Citations
181	Identification and characterization of a novel nanobody against human placental growth factor to modulate angiogenesis. Molecular Immunology, 2016, 78, 183-192.	2.2	22
182	Chromosome rearrangement in Leishmania mexicana M379. Molecular and Biochemical Parasitology, 1991, 46, 53-60.	1.1	21
183	Cloning and characterization of the dromedary (Camelus dromedarius) neonatal Fc receptor (drFcRn). Developmental and Comparative Immunology, 2006, 30, 1203-1215.	2.3	21
184	TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation. Journal of Thrombosis and Haemostasis, 2011, 9, 2268-2277.	3.8	21
185	The genome-wide binding profile of the Sulfolobus solfataricustranscription factor Ss-LrpB shows binding events beyond direct transcription regulation. BMC Genomics, 2013, 14, 828.	2.8	21
186	Expanded target and cofactor repertoire for the transcriptional activator LysM from Sulfolobus. Nucleic Acids Research, 2013, 41, 2932-2949.	14.5	21
187	Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20. New Biotechnology, 2018, 45, 69-79.	4.4	21
188	Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting. Oncotarget, 2018, 9, 17282-17299.	1.8	21
189	Differential association of linker histones H1 and H5 with telomeric nucleosomes in chicken erythrocytes. Nucleic Acids Research, 1994, 22, 5635-5639.	14.5	20
190	Inhibiting the Ca 2+ Influx Induced by Human CSF. Cell Reports, 2017, 21, 3310-3316.	6.4	20
191	Nanobody-Based high-performance immunosorbent for selective beta 2-microglobulin purification from blood. Acta Biomaterialia, 2020, 107, 232-241.	8.3	20
192	Direct Immobilization of Engineered Nanobodies on Gold Sensors. ACS Applied Materials & Interfaces, 2021, 13, 17353-17360.	8.0	20
193	Antibody technology in proteomics. Briefings in Functional Genomics & Proteomics, 2008, 7, 275-282.	3.8	19
194	Structural Basis for the Specific Neutralization of Stx2a with a Camelid Single Domain Antibody Fragment. Toxins, 2018, 10, 108.	3.4	19
195	Identification of New DR5 Agonistic Nanobodies and Generation of Multivalent Nanobody Constructs for Cancer Treatment. International Journal of Molecular Sciences, 2019, 20, 4818.	4.1	19
196	A Synthetic Camel Anti-Lysozyme Peptide Antibody (Peptibody) with Flexible Loop Structure Identified by High-Resolution Affinity Mass Spectrometry. Chemistry - A European Journal, 2006, 12, 1915-1923.	3.3	18
197	Blocking EGFR Activation with Antiâ€EGF Nanobodies via Two Distinct Molecular Recognition Mechanisms. Angewandte Chemie - International Edition, 2018, 57, 13843-13847.	13.8	18
198	Fast One-Step Ultrasensitive Detection of Toxocara canis Antigens by a Nanobody-Based Electrochemical Magnetosensor. Analytical Chemistry, 2019, 91, 11582-11588.	6.5	18

#	Article	IF	Citations
199	Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33. International Journal of Molecular Sciences, 2020, 21, 310.	4.1	18
200	Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha. Frontiers in Immunology, 2021, 12, 777524.	4.8	18
201	Cytoplasmic versus periplasmic expression of site-specifically and bioorthogonally functionalized nanobodies using expressed protein ligation. Protein Expression and Purification, 2017, 133, 25-34.	1.3	16
202	LlamaÂperipheral B-cell populations producing conventional and heavy chain-only IgG subtypes are phenotypically indistinguishable but immunogenetically distinct. Immunogenetics, 2019, 71, 307-320.	2.4	16
203	An innovative approach in the detection of Toxocara canis excretory/secretory antigens using specific nanobodies. International Journal for Parasitology, 2019, 49, 635-645.	3.1	16
204	Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102103.	3.3	16
205	Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its function. Iranian Journal of Basic Medical Sciences, 2018, 21, 260-266.	1.0	16
206	Isolation of Antigen-Specific Nanobodies. , 2010, , 251-266.		15
207	Generation of Anti-infectome/Anti-proteome Nanobodies. Methods in Molecular Biology, 2011, 790, 239-259.	0.9	15
208	Affinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies. PLoS Neglected Tropical Diseases, 2012, 6, e1902.	3.0	15
209	Structural basis for the high specificity of a Trypanosoma congolense immunoassay targeting glycosomal aldolase. PLoS Neglected Tropical Diseases, 2017, 11, e0005932.	3.0	15
210	Unbiased Immunization Strategy Yielding Specific Nanobodies against Macadamia Allergen of Vicilin-like Protein for Immunoassay Development. Journal of Agricultural and Food Chemistry, 2021, 69, 5178-5188.	5.2	15
211	Identification of a novel, nanobodyâ€induced, mechanism of TAFI inactivation and its in vivo application. Journal of Thrombosis and Haemostasis, 2014, 12, 229-236.	3.8	14
212	Generation of VHH antibodies against the Arabidopsis thaliana seed storage proteins. Plant Molecular Biology, 2014, 84, 83-93.	3.9	14
213	Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1. Thrombosis and Haemostasis, 2016, 116, 1032-1040.	3.4	14
214	Non-canonical roles of connexins. Progress in Biophysics and Molecular Biology, 2020, 153, 35-41.	2.9	14
215	A simple quantitative affinity capturing assay of poliovirus antigens and subviral particles by single-domain antibodies using magnetic beads. Journal of Virological Methods, 2011, 173, 300-305.	2.1	13
216	Resolution of an immunodiagnostic dilemma: Heavy chain chimeric antibodies for species in which plasmocytomas are unknown. Molecular Immunology, 2013, 53, 140-148.	2.2	13

#	Article	IF	Citations
217	Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor. Biomolecules, 2021, 11, 63.	4.0	13
218	AAVâ€mediated delivery of an antiâ€BACE1 VHH alleviates pathology in an Alzheimer's disease model. EMBO Molecular Medicine, 2022, 14, e09824.	6.9	13
219	Influence of histones H1/H5 on the DNA coiling in the nucleosome â€" electric dichroism and birefringence study. International Journal of Biological Macromolecules, 1981, 3, 370-376.	7.5	12
220	A phage-displayed single domain antibody fused to alkaline phosphatase for detection of porcine circovirus type 2. Journal of Virological Methods, 2015, 213, 84-92.	2.1	12
221	Paradigm shift in the diagnosis of peste des petits ruminants: scoping review. Acta Veterinaria Scandinavica, 2020, 62, 7.	1.6	12
222	Scatter analysis of discrete-sized chromatin fragments favours a cylindrical organization. FEBS Journal, 1985, 151, 283-289.	0.2	11
223	Isolation and characterization of single-chain Fv genes encoding antibodies specific forDrosophila Poxnprotein. FEBS Letters, 1998, 437, 75-80.	2.8	11
224	Nanobodies, Single-Domain Antigen-Binding Fragments of Camelid Heavy-Chain Antibodies. , 2010, , 29-48.		11
225	Expression, purification and X-ray crystallographic analysis of theHelicobacter pyloriblood group antigen-binding adhesin BabA. Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 1631-1635.	0.8	11
226	Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies. Scientific Reports, 2016, 6, 35966.	3.3	11
227	Combinatorial Design of a Nanobody that Specifically Targets Structured RNAs. Journal of Molecular Biology, 2018, 430, 1652-1670.	4.2	11
228	Site-Specific Radioactive Labeling of Nanobodies. Methods in Molecular Biology, 2018, 1827, 505-540.	0.9	11
229	NIRF-Molecular Imaging with Synovial Macrophages-Targeting Vsig4 Nanobody for Disease Monitoring in a Mouse Model of Arthritis. International Journal of Molecular Sciences, 2019, 20, 3347.	4.1	11
230	Liposomal delivery of vascular endothelial growth factor/receptors and their inhibitors. Journal of Drug Targeting, 2020, 28, 379-385.	4.4	11
231	Recent developments in engineering and delivery of protein and antibody therapeutics. Current Opinion in Biotechnology, 2011, 22, 839-842.	6.6	10
232	In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody. Thrombosis and Haemostasis, 2014, 111, 824-832.	3.4	10
233	Structural basis of nanobody recognition of grapevine fanleaf virus and of virus resistance loss. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10848-10855.	7.1	10
234	Nanobody-Based Immunosensor Detection Enhanced by Photocatalytic-Electrochemical Redox Cycling. Analytical Chemistry, 2021, 93, 13606-13614.	6.5	10

#	Article	IF	Citations
235	Assembly of oligonucleosomes into a limit series of multimeric higher-order chromatin structures. FEBS Journal, 1985, 150, 441-442.	0.2	9
236	Limitations of the poly(glutamic acid) reconstitution method in the reassembly of mono- and dinucleosomes. Biochemistry, 1986, 25, 5043-5051.	2.5	9
237	Bacterial Two Hybrid: A Versatile One-Step Intracellular Selection Method. , 2012, 911, 135-150.		9
238	Development of a high affinity Affibodyâ€derived protein against amyloid Î²â€peptide for future Alzheimer's disease therapy. Biotechnology Journal, 2015, 10, 1668-1669.	3.5	9
239	Ultrasensitive Measurement of Ca²⁺ Influx into Lipid Vesicles Induced by Protein Aggregates. Angewandte Chemie, 2017, 129, 7858-7862.	2.0	9
240	CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma. OncoImmunology, 2021, 10, 2000699.	4.6	9
241	Putative regulatory sequences for the transcription of mini-exons in Trypanosoma brucei as revealed by S1 sensitivity. Gene, 1985, 36, 263-270.	2.2	8
242	Immunological Aspects of Scorpion Toxins: Current Status and Perspectives. Inflammation and Allergy: Drug Targets, 2011, 10, 358-368.	1.8	8
243	Selection of Specific Nanobodies against Lupine Allergen Lup an 1 for Immunoassay Development. Foods, 2021, 10, 2428.	4.3	8
244	The crystal structure of recombinant rat pancreatic RNase A. , 1999, 35, 1-12.		7
245	Structure and Function of Camelid VHH. , 2016, , 153-159.		7
246	Protection of discrete DNA fragments by the complex Hl-octamerhistones or H5-octamerhistonesafter micrococcal nuclease digestion. Nucleic Acids Research, 1981, 9, 3671-3680.	14.5	6
247	The regulated expression of an intrabody produces a mutant phenotype inDrosophila. FEBS Letters, 1998, 437, 81-86.	2.8	6
248	Development and Characterization of Nanobodies Targeting the Kupffer Cell. Frontiers in Immunology, 2021, 12, 641819.	4.8	6
249	Comparative filter binding study of H5 to nucleosome core particles, H1, H5 depleted chromatosomes and DNA fragments. Molecular Biology Reports, 1989, 13, 191-196.	2.3	5
250	Heavy-Chain-Only Antibody Expression and B-Cell Development in the Mouse. Critical Reviews in Immunology, 2006, 26, 377-390.	0.5	5
251	Generation of Nanobodies against SlyD and development of tools to eliminate this bacterial contaminant from recombinant proteins. Protein Expression and Purification, 2017, 137, 64-76.	1.3	5
252	Electrochemical detection of Toxocara canis excretory-secretory antigens in children from rural communities in Esmeraldas Province, Ecuador: association between active infection and high eosinophilia. Parasites and Vectors, 2020, 13, 245.	2.5	5

#	Article	IF	Citations
253	Reshaping nanobodies for affinity purification on protein a. New Biotechnology, 2020, 57, 20-28.	4.4	5
254	Development of Nanobodies against Mal de RÃo Cuarto virus major viroplasm protein P9-1 for diagnostic sandwich ELISA and immunodetection. Scientific Reports, 2021, 11, 20013.	3.3	5
255	Development of Neutralizing Multimeric Nanobody Constructs Directed against IL-13: From Immunization to Lead Optimization. Journal of Immunology, 2021, 207, 2608-2620.	0.8	5
256	Complete Genome Sequencing of Field Isolates of Peste des Petits Ruminants Virus from Tanzania Revealed a High Nucleotide Identity with Lineage III PPR Viruses. Animals, 2021, 11, 2976.	2.3	5
257	Versatile Application of Nanobodies for Food Allergen Detection and Allergy Immunotherapy. Journal of Agricultural and Food Chemistry, 2022, 70, 8901-8912.	5.2	5
258	Increased Expression of Adherens Junction Components in Mouse Liver following Bile Duct Ligation. Biomolecules, 2019, 9, 636.	4.0	4
259	Development of Nanobodies Targeting Peste des Petits Ruminants Virus: The Prospect in Disease Diagnosis and Therapy. Animals, 2021, 11, 2206.	2.3	4
260	Site-Selective Functionalization of Nanobodies Using Intein-Mediated Protein Ligation for Innovative Bioconjugation. Methods in Molecular Biology, 2019, 2033, 117-130.	0.9	4
261	Neutralizing Dromedary-Derived Nanobodies Against BotI-Like Toxin From the Most Hazardous Scorpion Venom in the Middle East and North Africa Region. Frontiers in Immunology, 2022, 13, 863012.	4.8	4
262	Preparation and purification of mononucleosome particles containing histone H5. FEBS Letters, 1980, 119, 93-96.	2.8	3
263	Single-Domain Antibodies. , 0, , 216-230.		3
264	Nanobody-Based Chromatin Immunoprecipitation. , 2012, 911, 491-505.		3
265	Dromedary immune response and specific Kv2.1 antibody generation using a specific immunization approach. International Journal of Biological Macromolecules, 2016, 93, 167-171.	7.5	3
266	Unique singleâ€domain antigen binding fragments derived from naturally occurring camel heavyâ€chain antibodies. Journal of Molecular Recognition, 1999, 12, 131-140.	2.1	3
267	Wheat germ inÂvitro translation to produce one of the most toxic sodium channel specific toxins. Bioscience Reports, 2014, 34, .	2.4	2
268	Blocking EGFR Activation with Antiâ€EGF Nanobodies via Two Distinct Molecular Recognition Mechanisms. Angewandte Chemie, 2018, 130, 14039-14043.	2.0	2
269	Intrabody Targeting HIF-1Î± Mediates Transcriptional Downregulation of Target Genes Related to Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 12335.	4.1	2
270	Sensitive Protein Detection Using Site-Specifically Oligonucleotide-Conjugated Nanobodies. Analytical Chemistry, 2022, 94, 10054-10061.	6.5	2

#	Article	IF	Citations
271	Guided Evolution of Recombinant Bombyx mori Acetylcholinesterase II by Homology Modeling to Change Pesticide Sensitivity. International Journal of Molecular Sciences, 2018, 19, 3366.	4.1	1
272	Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications. Methods in Molecular Biology, 2022, 2446, 3-17.	0.9	1
273	Neutron scattering of chromatin multinucleosomes. Physica B: Physics of Condensed Matter & C: Atomic, Molecular and Plasma Physics, Optics, 1986, 136, 265-267.	0.9	0
274	Corrigendum to: Isolation and characterization of single-chain Fv genes encoding antibodies specific for Drosophila Poxn protein (FEBS 20963). FEBS Letters, 1999, 443, 80-80.	2.8	0
275	Bio-chemical Process Monitoring with Terahertz Sensor. NATO Science for Peace and Security Series B: Physics and Biophysics, 2017, , 29-36.	0.3	0
276	Nanobodies against the metal binding domains of ATP7B as tools to study copper transport in the cell. Metallomics, 2020, 12, 1941-1950.	2.4	0
277	Abstract 4627: Generation and characterization of non-competitive furin-inhibiting nanobodies. , 2012, , .		0
278	Nanobodies as binding-chaperones stabilize the recombinant Bombyx mori acetylcholinesterase and protect the enzyme activity in pesticide detection. Enzyme and Microbial Technology, 2022, 155, 109992.	3.2	0
279	Cytoplasmic Expression of Nanobodies with Formylglycine Generating Enzyme Tag and Conversion to a Bio-Orthogonal Aldehyde Group. Methods in Molecular Biology, 2022, 2446, 357-371.	0.9	0